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Junctional Adhesion Molecule C Mediates Leukocyte Adhesion
to Rheumatoid Arthritis Synovium
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Objective. Leukocyte infiltration into the rheuma-
toid arthritis (RA) synovium is a multistep process in
which leukocytes leave the bloodstream and invade the
synovial tissue (ST). Leukocyte transendothelial migra-
tion and adhesion to RA ST requires adhesion mole-
cules on the surface of endothelial cells and RA ST
fibroblasts. This study was undertaken to investigate
the role of junctional adhesion molecule C (JAM-C) in
mediating leukocyte recruitment and retention in the
RA joint.
Methods. Immunohistologic analysis was per-
formed on RA, osteoarthritis (OA), and normal ST
samples to quantify JAM-C expression. Fibroblast
JAM-C expression was also analyzed using Western
blotting, cell surface enzyme-linked immunosorbent as-
say, and immunofluorescence. To determine the role of
JAM-C in leukocyte retention in the RA synovium, in
vitro and in situ adhesion assays and RA ST fibroblast
transmigration assays were performed.
Results. JAM-C was highly expressed by RA ST
lining cells, and its expression was increased in OA ST
and RA ST endothelial cells compared with normal ST
endothelial cells. JAM-C was also expressed on the
surface of OA ST and RA ST fibroblasts. Furthermore,
we demonstrated that myeloid U937 cell adhesion to
both OA ST and RA ST fibroblasts and to RA ST was
dependent on JAM-C. U937 cell migration through an
RA ST fibroblast monolayer was enhanced in the pres-
ence of neutralizing antibodies against JAM-C.
Conclusion. Our results highlight the novel role
of JAM-C in recruiting and retaining leukocytes in the
RA synovium and suggest that targeting JAM-C may be
important in combating inflammatory diseases such as
RA.
Rheumatoid arthritis (RA) is a chronic, systemic
inflammatory disease that is characterized by erosive
synovitis. The disease process is marked by neovascular-
ization of the synovium, synovial lining cell hyperplasia,
and inflammatory cell infiltration into the joint. Leuko-
cyte extravasation into the synovium and synovial fluid is
an active process mediated by cellular adhesion mole-
cules (1). After traversing the endothelium, leukocytes
adhere to other cells, including fibroblast synovial tissue
(ST) lining cells, via specific adhesion molecule interac-
tions (1). It has previously been shown that these RA ST
fibroblasts express a number of different types of cellu-
lar adhesion molecules, including integrins (2), members
of the immunoglobulin superfamily (3), and selectins
(2). In addition, these cellular adhesion molecules act as
costimulators, and therefore, these interactions may lead
to activation of inflammatory cells and perpetuation of
inflammation in the RA synovium.
Junctional adhesion molecules (JAMs) are a sub-
family of the immunoglobulin superfamily that have
been identified at tight junctions between epithelial cells
and endothelial cells (ECs). To date, 5 members of the
JAM family have been identified: JAM-A (4), JAM-B
(5,6), JAM-C (7,8), JAM4 (9), and JAM-like (JAML)
(10). All JAMs have an extracellular domain with 2
Ig-like domains, a single transmembrane sequence, and
a short cytoplasmic tail that contains adaptor molecule
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binding motifs (11), and a putative site for phosphory-
lation by protein kinase C (12,13). JAM-A, JAM-B, and
JAM-C have been shown to interact with each other in
homophilic interactions, and heterophilic interactions
between JAM-B and JAM-C have also been observed
(7). In addition to binding interactions between family
members, other receptors have been identified that bind
JAMs. JAM-A has been shown to be a ligand for
lymphocyte function–associated antigen 1 (14) on the
surface of leukocytes and integrin v3 in cis on the
surface of ECs (15,16). In addition, JAM-B is a ligand
for very late activation antigen 4 on the surface of
leukocytes (17), while JAM-C is a ligand for the leuko-
cyte integrins Mac-1 and x2 (18,19).
JAMs have previously been shown to be media-
tors in a number of disease processes, including disease
models of inflammation. JAM-A has been implicated in
monocyte and neutrophil infiltration in models of skin
inflammation, experimental meningitis, cardiac
ischemia-reperfusion, and hepatic ischemia-reperfusion
(4,20–22). In addition, both JAM-B and JAM-C play a
role in the development of contact dermatitis by pro-
moting leukocyte recruitment into the skin (23), while
JAM-C mediates neutrophil transendothelial migration
in murine models of acute peritonitis (24), pancreatitis
(25), and pulmonary inflammation (26).
Recently, Palmer et al (27) showed that JAM-C
plays a role in experimental arthritis. They demonstrated
that administration of an anti–JAM-C antibody de-
creased the severity and delayed the onset of antigen-
induced and serum-induced arthritis in mice, respec-
tively. However, the mechanism by which JAM-C acts to
mediate inflammation in RA has not been definitively
shown. Therefore, we investigated the expression of
JAM-C in RA synovium and on RA ST fibroblasts, and
the role that JAM-C plays in leukocyte adhesion to RA
ST fibroblasts and RA ST. We demonstrate that JAM-C
plays a role in leukocyte adhesion to OA and RA
synovium, suggesting that the reduced arthritis observed
by the neutralization of JAM-C in animal models is due
in part to reduced leukocyte adhesion in the joint.
MATERIALS AND METHODS
Antibodies and reagents. Recombinant human tumor
necrosis factor  (TNF) (ED50 0.02–0.05 ng/ml), stromal
cell–derived factor 1 (SDF-1), and goat anti-human
JAM-A, JAM-B, and JAM-C antibodies were purchased from
R&D Systems (Minneapolis, MN). Neutralizing rat anti-
mouse/human JAM-C antibodies (H33 and F26) that were
previously shown to recognize human JAM-C were used in all
functional assays (8). Both antibodies were tested because of
their differing properties; H33 inhibits both JAM-C ho-
mophilic interactions and JAM-B–JAM-C heterophilic inter-
actions, while F26 inhibits JAM-C homophilic interactions
only (28). Rabbit anti-human P-selectin and mouse anti-
human Mac-1 were purchased from BD PharMingen (San
Diego, CA). Rabbit anti-human actin antibody was obtained
from Sigma (St. Louis, MO). Normal goat IgG and rat IgG
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Horseradish peroxidase–conjugated rabbit anti-goat an-
tibody was obtained from Molecular Probes (Eugene, OR).
Alexa Fluor 488 donkey anti-goat antibodies were purchased
from Invitrogen (Carlsbad, CA).
Cell culture. RA and OA ST samples were obtained
from patients undergoing arthroplasty or synovectomy. Nor-
mal ST samples were obtained at autopsy or from patients
undergoing amputation, within 24 hours after death or limb
removal. The protocol for obtaining patient consent and for
the use of human tissue was approved by the Institutional
Review Board at the University of Michigan. Fresh ST samples
were minced and digested in a solution of Dispase, collage-
nase, and DNase to isolate fibroblasts (29). The cells were
cultured in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS) in 175-mm tissue culture flasks at 37°C in a
humidified atmosphere with 5% CO2. Cells were used at
passage 5–9, at which time they were a homogeneous, 85–95%
confluent population of fibroblasts. U937 cells (human mono-
cytic lymphoma cell line) were cultured in RPMI supple-
mented with 10% FBS in 175-mm tissue culture flasks at 37°C
in a humidified atmosphere with 5% CO2.
Immunohistologic analysis. Frozen ST samples ob-
tained from RA, OA, and normal patients were cut into
5-m sections and stained using an immunoperoxidase
method. Slides were fixed in cold acetone for 10 minutes.
Following incubation with 3% H2O2 for 30 minutes to block
endogenous peroxidase, ST samples were blocked with 10%
horse serum in phosphate buffered saline (PBS) at 37°C for 1
hour, and then incubated with goat anti-human JAM-C (10
g/ml) or purified nonspecific goat IgG for 1 hour at room
temperature in blocking buffer. The ST samples were washed
with PBS, and a 1:100 dilution (in blocking buffer) of biotin-
ylated horse anti-goat antibody was added and incubated for
an additional 1 hour at room temperature. After washing,
antibody binding was detected using a Vectastain ABC Elite
kit (Vector, Burlingame, CA) and the chromogen 3,3-
diaminobenzidine (DAB) (Vector). ST samples were counter-
stained with Gill’s hematoxylin. Staining was evaluated by a
pathologist (GKH) who was blinded with regard to sample
group. Slides were examined for cellular immunoreactivity,
and cell types were distinguished based on their characteristic
morphology. ST inflammation was assigned a score from 0 to
4, depending on the degree of inflammatory cell invasion. ST
vascularity was assigned a score from 1 to 4, depending on the
vessel density in the ST. The percentage of cells expressing
JAMs was analyzed on synovial lining cells and on ECs.
Cell lysis and Western blotting. RA ST fibroblasts
were lysed with lysis buffer (175 l) (Cell Lysis Buffer; Cell
Signaling Technology, Beverly, MA) containing protease in-
hibitors. The protein concentration in each extract was deter-
mined using a Pierce bicinchoninic acid protein assay (Pierce,
Rockford, IL). Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis was performed on cell lysates after equal
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protein loading, according to the method of Laemmli (30), and
proteins were transferred onto a nitrocellulose membrane
using a semi-dry transblotting apparatus (Bio-Rad, Hercules,
CA). Blots were probed using goat polyclonal antibodies
specific for JAM-C. The immunoblots were stripped and
reprobed with rabbit anti–-actin to verify equal loading. The
immunoreactive protein bands were visualized by enhanced
chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Densitometric analysis of the bands was performed using
Un-Scan-It software, version 5.1 (Silk Scientific, Orem, UT).
Cell surface enzyme-linked immunosorbent assay
(ELISA). RA ST fibroblasts (1  105/well) were seeded in
96-well plates (BD Falcon, Bedford, MA). Upon reaching
confluence, following overnight serum starvation, RA ST
fibroblasts were left untreated or were stimulated with TNF
(25 ng/ml) for 24 hours. Cells were fixed with 3.7% formalin in
PBS, and cell surface ELISAs were performed as previously
described (31). Goat polyclonal antibodies specific for JAM-C
(10 g/ml) were used, and the plates were read with an ELISA
reader (Bio-Rad) at 450 nM.
Immunofluorescence staining. RA ST fibroblasts were
plated at 10,000 cells/well in 8-well Labtek chamber slides.
After overnight serum starvation, cells were left untreated or
were stimulated with TNF (25 ng/ml) for 24 hours. Cells were
washed with PBS, fixed with 4% formalin for 30 minutes at
room temperature, washed again with PBS, and fixed with
ice-cold methanol for 5 minutes. Blocking was performed by
adding 5% donkey serum in PBS for 1 hour at room temper-
ature. JAM-C–specific primary antibody (5 g/ml) was added
for 1 hour at room temperature in blocking buffer. Following
washing, Alexa Fluor 488–conjugated donkey anti-goat anti-
body (10 g/ml) was added for 1 hour at room temperature.
Cells were washed with PBS, and 4,6-diamidino-2-
phenylindole (Molecular Probes) nuclear stain was added for 5
minutes at a 1:2,000 dilution. Slides were dehydrated,
mounted, and coverslipped. Immunofluorescence staining was
detected using an Olympus FV-500 confocal microscope
(Olympus America, Melville, NY).
Flow cytometric analysis. U937 cells were collected
and washed twice in fluorescence-activated cell sorter (FACS)
buffer (PBS/1% FBS/0.02% sodium azide) and resuspended at
a final concentration of 5  105 cells per tube. Cells were then
incubated with goat anti-human JAM-A, JAM-B, or JAM-C,
at a concentration of 5 g/ml diluted in FACS buffer, for 30
minutes at 4°C. Following washing with FACS buffer, cells
were resuspended in blocking buffer (30% donkey serum/
FACS buffer) and incubated for 30 minutes at 4°C. Cells were
then incubated with Alexa Fluor 488 donkey anti-goat second-
ary antibody at a concentration of 5 g/ml in blocking buffer
for 30 minutes at 4°C. Secondary antibody with goat IgG was
used as a negative control. At the end of the experiment, cells
were washed twice with FACS buffer and resuspended in
PBS/1% formaldehyde until analysis. JAM expression on U937
cells was analyzed using a BD FACSAria high-speed cell sorter
(BD Biosciences, San Jose, CA), and the percentage of
positively stained cells was determined.
In vitro cell adhesion assay. Adhesion of U937 cells to
RA ST or OA ST fibroblasts grown to confluence in 96-well
plates was tested. RA ST fibroblasts were serum starved
overnight, and 1 hour prior to assay, the fibroblasts were
preincubated with neutralizing antibodies H33 and F26 against
JAM-C (25 g/ml) or irrelevant rat IgG controls. U937 cells
were left untreated or were stimulated with 100 ng/ml phorbol
myristate acetate (PMA) overnight. The following day, the
cells were collected and labeled with Calcein AM fluorescent
dye (5 M) (Invitrogen) for 20 minutes. After washing twice,
1  105 cells were added to each well and incubated for 20
minutes at room temperature or at 37°C. At the end of the
assay, nonadherent cells were washed off, and fluorescence
was measured using a Synergy HT fluorescence plate reader
(BioTek Instruments, Winooski, VT).
Stamper-Woodruff assay. In situ adhesion assays were
performed as previously described (28). Briefly, frozen RA ST
samples were cut into 5-m sections and incubated with
neutralizing antibodies against JAM-C (H33 or F26) or irrel-
evant IgG control (rat IgG). Neutralizing rabbit antibody
against P-selectin was used as a positive control (32). U937
cells were labeled with Calcein AM fluorescent dye (5 M)
(Invitrogen) for 20 minutes. After incubation, medium was
removed, and 1  105 fluorescence-labeled U937 cells were
added to all sections and incubated for 1 hour at room
temperature. At the end of the experiment, nonadherent cells
were washed off. Fluorescent U937 cell adhesion to RA ST
was counted by an investigator (BJR) who was blinded with
regard to treatment group, using a BX51 Fluorescence Micro-
scope System and DP Manager imaging software (Olympus
America).
Leukocyte–RA ST fibroblast transmigration assay.
RA ST fibroblasts (1.5  104) were grown to confluence in
Costar Transwell culture inserts in 24-well tissue culture plates
(10-mm diameter polycarbonate membranes with 8-m diam-
eter pores) (Corning Costar, Cambridge, MA). At the start of
the assay, cultures were washed twice, and RPMI/0.5% bovine
serum albumin was loaded into the lower compartment of each
plate with or without SDF-1 (200 ng/ml). U937 cells (2  105)
were added to each filter in the presence of neutralizing
anti–JAM-C antibody (H33 or F26) or irrelevant IgG control
and incubated for 2 or 4 hours at 37°C. At the end of the assay,
the transmigrated cells were collected from the lower chamber,
and their number was determined using a CyQuant cell
enumeration kit (Invitrogen).
Statistical analysis. Data were analyzed using Stu-
dent’s t-test assuming equal variances. Data are reported as the
mean  SEM. P values less than 0.05 were considered
significant.
RESULTS
Expression of JAM-C on RA synovial lining cells
and ECs. JAM-C expression was determined in ST
samples from normal subjects, OA patients, and RA
patients using immunohistochemical staining. JAM-C
has previously been shown to be expressed in both ST
lining cells and ECs in both OA and RA patients by
Palmer et al (27); however, JAM-C expression was not
quantified in each cell type within the ST samples. As
expected, both synovial inflammation and vascularity
were significantly enhanced in RA compared with
normal ST samples (P  0.05) (data not shown).
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JAM-C expression was analyzed in both ECs and
synovial lining cells by a pathologist (GKH) who was
blinded with regard to cell type. Figure 1 shows
representative photomicrographs of RA ST samples
immunostained with JAM-C antibody (Figure 1A) or
irrelevant goat IgG (Figure 1B). ECs within both OA
and RA ST expressed high levels of JAM-C (mean 
SEM 98  1.7% and 94  1.7%, respectively), while
ECs within normal ST expressed significantly less
JAM-C than did ECs within RA ST (83  3.9%, P 
0.05) (Figure 1C). In addition, we found that JAM-C
was highly expressed by ST lining cells from normal,
OA, and RA ST (99  1.0%, 95  2.0%, and 85
3.5%, respectively), with lining cell expression in
normal and OA ST significantly greater than that in
RA ST (P  0.05) (Figure 1D).
Expression of JAM-C in RA ST fibroblasts. Pre-
viously, JAM-C messenger RNA (mRNA) has been
shown to be present in RA ST fibroblasts (27). To
determine whether JAM-C was expressed by RA ST
fibroblasts at the protein level and whether it was
regulated by the proinflammatory cytokine TNF, West-
ern blots were performed. We chose TNF to stimulate
RA ST fibroblasts, since TNF is a pluripotent cytokine
important in RA pathogenesis and has been shown to
induce RA ST fibroblast surface expression of other
adhesion molecules (33,34). Western blotting revealed a
35-kd protein band corresponding to JAM-C; however,
no increase in expression was observed following over-
night stimulation with TNF (Figure 2A).
In addition, we performed a cell surface ELISA
to determine if JAM-C was expressed on the surface
of RA ST fibroblasts. We found that JAM-C was
Figure 2. JAM-C expression in RA ST fibroblasts. A, Mean and SEM
total number of pixels showing JAM-C expression in RA ST fibroblasts
left untreated or cultured with tumor necrosis factor  (TNF) for 24
hours. Western blots showed a 35-kd protein band consistent with the
molecular weight of JAM-C; however, no differences were observed
after stimulation with TNF. B, Mean and SEM fold change in
expression of JAM-C on the cell surface of RA ST fibroblasts left
untreated or cultured with TNF, determined by cell surface enzyme-
linked immunosorbent assay. Surface expression of JAM-C on RA ST
fibroblasts did not change after stimulation with TNF. C, Surface
expression and localization of IgG control and JAM-C on RA ST
fibroblasts, examined using immunofluorescence and confocal micros-
copy. JAM-C was expressed throughout the surface, and no difference
in expression was noted between adjacent fibroblasts in the presence
or absence of TNF. NS  nonstimulated (see Figure 1 for other
definitions).
Figure 1. Immunohistologic analysis of junctional adhesion molecule
C (JAM-C) in synovial tissue (ST) samples from normal (NL) subjects,
patients with osteoarthritis (OA), and patients with rheumatoid arthri-
tis (RA). Frozen sections of normal, OA, and RA ST were stained for
JAM-C expression. A and B, Representative photomicrographs of
JAM-C (A) and IgG control (B) expression in RA ST (original
magnification  400). C, Mean and SEM JAM-C expression in normal
ST, OA ST, and RA ST endothelial cells (ECs). JAM-C was more
highly expressed in OA ST (98%) and RA ST (94%) ECs than in
normal ST (83%) ECs. D, Mean and SEM JAM-C expression in
normal ST, OA ST, and RA ST lining cells. JAM-C was more highly
expressed in normal ST (99%) and OA ST (95%) lining cells than in
RA ST (85%) lining cells.
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present on the surface of these cells, and similar to the
results of Western blotting, no increase in expression
was observed following stimulation with TNF (Fig-
ure 2B). To visualize JAM-C expression on RA ST
fibroblasts, immunofluorescence was performed via
confocal microscopy. JAM-C was expressed on the
surface of RA ST fibroblasts, but was not confined to
cell junctions (Figure 2C). Overnight stimulation with
TNF or plating on gelatin-coated plates did not
result in an increase or redistribution of JAM-C on
the cell surface. Similar results were observed with
respect to OA ST fibroblasts, as JAM-C was expressed
on the cell surface but not confined to the cell surface
(data not shown). Moreover, the distribution of
JAM-C on the surface of OA ST fibroblasts did not
change after stimulation with TNF or plating on
gelatin-coated wells. Taken together, these results
indicate that while JAM-C is present on the cell
surface of RA and OA ST fibroblasts, its expression is
not regulated by TNF.
JAM-C mediates U937 cell adhesion to RA ST
fibroblasts. To determine the role that JAM-C plays in
mediating leukocyte adhesion to RA ST fibroblasts, we
performed in vitro adhesion assays. We found that either
of the neutralizing anti–JAM-C antibodies, H33 or F26,
significantly inhibited adhesion of U937 cells to RA ST
fibroblasts, by 14% and 21%, respectively (P  0.05
versus IgG control) (Figure 3A). Incubation with an
antibody against Mac-1 also significantly inhibited U937
cell adhesion to RA ST fibroblasts, by 21% (P  0.05
versus IgG control) (Figure 3A). Moreover, when RA
ST fibroblasts were preincubated with a combination of
F26 and anti–Mac-1 antibodies, an additive inhibition
was observed; adhesion decreased by 34% (P  0.05)
Figure 3. JAM-C mediates adhesion of untreated or phorbol myristate acetate (PMA)–stimulated U937 cells to RA and OA
ST fibroblasts. The percentage of maximal adhesion was defined as the number of adherent cells on the ST sections divided
by the number of adherent cells on the control sections. A, Inhibition of U937 cell adhesion to RA ST fibroblasts by both of
the neutralizing antibodies against JAM-C, F26 (79% of maximal adhesion) and H33 (86% of maximal adhesion), and by an
anti–Mac-1 antibody (79% of maximal adhesion). B, Additive inhibitory effect on U937 cell adhesion to RA ST fibroblasts of
F26 combined with anti–Mac-1 (66% of maximal adhesion). C, Inhibition of PMA-stimulated U937 cell adhesion to RA ST
fibroblasts at 37°C by F26 (71% of maximal adhesion). D, Inhibition of PMA-stimulated U937 cell adhesion to OA ST
fibroblasts at 37°C by F26 (77% of maximal adhesion). Bars show the mean and SEM. See Figure 1 for other definitions.
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(Figure 3B). In addition, the F26 antibody inhibited PMA-
stimulated U937 cells from binding to RA ST fibroblasts
by 29% (P  0.05 versus IgG control) (Figure 3C).
To see if this effect was specific to RA ST
fibroblasts, we performed in vitro adhesion assays
between OA ST fibroblasts and U937 cells. We found
that the neutralizing anti–JAM-C antibody F26 signif-
icantly inhibited adhesion of PMA-stimulated U937
cells to OA ST fibroblasts, by 23% (P  0.05 versus
IgG control), a level similar to that observed with RA
ST fibroblasts (Figure 3D). These results suggest that
JAM-C plays a role in mediating leukocyte adhesion
to RA ST and OA ST, largely through its interaction
with Mac-1.
JAM-C mediates U937 cell adhesion to RA syno-
vium. To determine if JAM-C plays a functional role in
mediating leukocyte adhesion to RA ST, we performed
in situ cell adhesion assays. We found that myeloid U937
cells preferentially adhered to the synovial lining, which
contains myeloid and fibroblast cells, and blood vessels
(Figure 4). As a positive control, we used a neutralizing
antibody against P-selectin, since P-selectin has previ-
ously been shown to meditate human monocyte adhe-
sion to RA ST (32). Anti–P-selectin antibody inhibited
U937 adhesion by 59% (41% of maximal binding) (P 
0.05 versus IgG control). Importantly, anti–JAM-C neu-
tralizing antibodies H33 and F26 decreased U937 cell
adhesion to RA ST by 40% (60% of maximal binding)
and 51% (49% of maximal binding), respectively (P 
0.05 versus IgG control, for both H33 and F26).
Both anti–JAM-C antibodies were examined due
to their different binding specificities. Previously, both
H33 and F26 have been shown to neutralize JAM-C
homophilic interactions, but only H33 has been shown to
inhibit JAM-B–JAM-C heterophilic interactions (8,28).
Since there was no significant difference between the
ability of the anti–P-selectin antibody and the anti–
JAM-C antibodies to inhibit U937 cell adhesion, these
results indicated that JAM-C was an important mediator
of leukocyte adhesion to inflamed RA synovium.
JAM-C mediates U937 cell retention in a model
of myeloid RA ST fibroblast transmigration. To further
study the functional role of JAM-C in RA ST, we
performed myeloid RA ST fibroblast transmigration
assays. Interestingly, incubation with either H33 or F26
resulted in increased U937 cell migration at 2 hours, by
1.4-fold and 1.2-fold, respectively (P  0.05 versus IgG
control, for both H33 and F26) (Figure 5). This migra-
tion persisted at 4 hours, with a 1.3-fold increase in
migration following incubation with H33 (P  0.05
versus IgG control) and a 1.2-fold increase following
incubation with F26. These results further suggest that
JAM-C normally plays a role in the retention of leuko-
cytes in the RA synovium, preventing egress of leuko-
Figure 4. JAM-C mediates adhesion of U937 cells to RA synovium. Stamper-Woodruff in situ assays were
performed using frozen RA ST sections and fluorescence-labeled U937 cells. Left, Mean and SEM percentage
of maximal binding, defined as the number of adherent cells on the test sections divided by the number of
adherent cells on the control sections, of U937 cells by IgG, F26, H33, and anti–P-selectin. U937 cell adhesion
was inhibited to a similar degree by both of the anti–JAM-C antibodies, F26 (49% of maximal binding) and H33
(60% of maximal binding), and by anti–P-selectin (41% of maximal binding). Right, Most U937 cells adhered to
the blood vessels and synovial lining (arrows) (original magnification  400). See Figure 1 for definitions.
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cytes through the fibroblast monolayer, an effect which
can be reversed by anti–JAM-C antibodies.
Expression of JAM-A, but not JAM-B or JAM-C,
on U937 cells. Previous studies have demonstrated that
the JAM-C ligand Mac-1 is expressed on monocytes and
U937 cells (35). Therefore, we wanted to determine if
JAM-B, another ligand for JAM-C, is expressed on the
surface of U937 cells. Only JAM-A was found to be
expressed on the surface of U937 cells (Figure 6).
Interestingly, no JAM-B or JAM-C was detected, indi-
cating that neither homophilic JAM-C nor heterophilic
JAM-B–JAM-C interactions mediate U937 adhesion to
RA ST or OA ST fibroblasts.
DISCUSSION
In the current study, we have shown that JAM-C
is expressed on both ECs and lining cells in normal, OA,
and RA ST. While Palmer et al (27) showed that JAM-C
is expressed in RA ST and OA ST (27), we found that
JAM-C was more highly expressed in ECs in RA and
OA ST than ECs in normal ST. In contrast, Ludwig et al
(23) have shown that in a mouse model of contact
dermatitis, levels of JAM-C mRNA and protein in ECs
were similar in normal skin and inflamed skin (23).
However, JAM-C has been shown to be overexpressed
in both smooth muscle cells and endothelium during
arteriosclerosis and to have increasing expression with
lesion progression (36). Similarly, JAM-C was shown to
be up-regulated in ECs in a mouse model of acute
pancreatitis compared with control animals (25). Taken
together, these results suggest that JAM-C is up-
regulated on ECs in various inflammatory states.
After finding JAM-C expression in OA ST and
RA ST lining cells, we wanted to determine if JAM-C
was expressed in OA ST and RA ST fibroblasts and
where it was localized in these cells. Recently, Palmer et
al (27) demonstrated that JAM-C mRNA was expressed
in RA ST fibroblasts. Our results confirmed these
findings at the protein level and demonstrated that
JAM-C expression was not dependent on the proinflam-
matory cytokine TNF. Moreover, we showed that
JAM-C is expressed on the surface of RA ST fibroblasts
and that its expression is not limited to cell–cell contact
points, but rather distributed across the cell surface.
Furthermore, the distribution pattern of JAM-C in RA
ST fibroblasts was not altered by the addition of TNF
or by plating the cells in the presence of a polarizing
extracellular matrix molecule. We observed a similar
expression pattern for OA ST fibroblasts.
JAM-C has previously been shown to be ex-
pressed on the surface of human dermal, lung, and
corneal fibroblasts (37). Morris et al (37) found that
under quiescent conditions, JAM-C localizes to the
adherens-like junctions between adjacent fibroblasts.
Under inflammatory conditions, JAMs redistribute on
Figure 6. Mean percentage of U937 cells expressing junctional adhe-
sion molecule A (JAM-A), JAM-B, and JAM-C. Flow cytometric
analysis was performed on U937 cells immunostained with antibodies
against JAM-A, JAM-B, or JAM-C, or IgG control. U937 cells
expressed JAM-A, but not JAM-B or JAM-C.
Figure 5. JAM-C mediates U937 cell adhesion in a model of myeloid
RA ST fibroblast transmigration. U937 cell migration through RA ST
fibroblast monolayers grown on Transwell inserts, in response to
incubation with stromal cell–derived factor 1 for 2 or 4 hours, was
studied. Both neutralizing anti–JAM-C antibodies, F26 and H33,
enhanced migration of U937 cells through the fibroblast monolayer.
Bars show the mean and SEM fold change in migrated cells in test
wells compared with migration in IgG control–treated wells. See
Figure 1 for definitions.
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ECs from cell contact points to the cell surface (38).
JAM-C has been shown to be partially redistributed to
the cell surface and away from inter-EC contacts follow-
ing stimulation with oxidized lipoproteins (36). There-
fore, the distribution pattern of JAM-C in OA and RA
ST fibroblasts suggests that it may play a role in both
fibroblast junctional stability and in mediating leukocyte
retention, rather than merely stabilizing fibroblast junc-
tions.
Based on the observed expression of JAM-C in
OA ST and RA ST, as well as OA ST and RA ST
fibroblasts, we sought to determine if JAM-C played a
role in mediating leukocyte adhesion to the RA syno-
vium. Previous studies have demonstrated that JAMs
play a role in binding leukocyte surface integrins
(14,17,18). Liberation of JAM-C from junctional com-
plexes on ECs can lead to apical expression of JAM-C
and possible interaction with Mac-1 (28). Under proath-
erosclerotic conditions, JAM-C is redistributed from the
EC junctional complex to the cell surface, which could
lead to additional adhesion of leukocytes, thus potenti-
ating the disease (36). Under these conditions, myeloid
THP-1 adhesion to ECs and transmigration of THP-1
cells through ECs was increased 2-fold (36). In addition,
platelet JAM-C has been shown to interact with the
leukocyte cell surface integrin Mac-1 to facilitate firm
adhesion between platelets and leukocytes (18). Those
investigators also demonstrated that U937 cells, which
express Mac-1, bind purified and immobilized JAM-C,
as well as JAM-C–transfected Chinese hamster ovary
cells (18).
In the present study, we showed JAM-C–
dependent U937 cell adhesion to OA ST and RA ST
fibroblasts and RA synovial sections. Neutralizing anti–
JAM-C antibodies, H33 and F26, and neutralizing anti–
Mac-1 antibody reduced adhesion between U937 cells
and RA ST fibroblasts to a similar degree. When the F26
anti–JAM-C antibody was added to the anti–Mac-1
antibody, the combination yielded an additive inhibitory
effect on adhesion. This indicates that JAM-C mediates
adhesion of U937 myeloid cells to RA ST fibroblasts in
part through its interaction with the integrin Mac-1.
In addition to mediating leukocyte adhesion,
JAMs play a primary role in the transmigration of
leukocytes across the endothelium. JAM-C has been
shown to promote lymphocyte and neutrophil transen-
dothelial migration (24,39). Under inflammatory condi-
tions, JAM-C has been shown to modulate the influx of
leukocytes through the endothelium (26). In a model of
acute pulmonary inflammation, leukocyte transendothe-
lial migration was increased in mice overexpressing
JAM-C specifically on their ECs (26). Moreover, JAM-C
has recently been shown to regulate unidirectional
monocyte transendothelial migration (40). Bradfield et
al (40) showed that blockade of JAM-B–JAM-C inter-
actions reduced monocyte numbers in extravascular
tissue by promoting increased reverse transmigration,
rather than by reducing transendothelial migration.
However, JAM-C was not shown to play a role in
neutrophil transendothelial migration under shear flow
conditions (41).
In addition to transendothelial migration, JAM-C
has been shown to play a role in transepithelial migra-
tion (19). Blocking JAM-C, by either monoclonal anti-
body or soluble recombinant JAM-C, inhibited the rate
of polymorphonuclear cell transepithelial migration
(19). However, in our study, we found that the addition
of anti–JAM-C antibodies resulted in an increase in
U937 cell migration through an RA ST fibroblast mono-
layer. It may be that RA ST fibroblasts are not polarized
cells and do not form tight junctions like ECs and
epithelial cells. Moreover, we have shown that JAM-C is
primarily located at the cell surface of RA ST fibroblasts
and is not selectively localized at adhesion points be-
tween adjacent fibroblasts. Therefore, we postulate that
JAM-C normally plays a role in leukocyte retention with
the RA synovium.
Our study was designed to determine JAM-C
expression in the synovium and to determine the role of
JAM-C in RA ST. We have shown that JAM-C is highly
expressed in OA and RA ST lining cells and ECs and on
the surface of OA and RA ST fibroblasts. Importantly,
we have demonstrated that JAM-C modulates the adhe-
sion to and retention of leukocytes in the RA synovium.
We therefore propose that JAM-C plays dual roles in
mediating arthritis. As was shown previously, JAM-C on
the surface of ECs mediates neutrophil ingress into the
arthritic synovium, and we now propose that JAM-C on
the surface of RA ST fibroblasts mediates the retention
of leukocytes in RA synovium. Taken together, these
results demonstrate the importance of JAM-C in RA
and suggest that targeting JAM-C may be important in
combating RA.
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